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Abstract 34 
 2
Resistance to endocrine therapy remains a major clinical problem in breast cancer. 35 
Genetic studies highlight the potential role of estrogen-receptor-α (ESR1) mutations, 36 
which show increased prevalence in the metastatic, endocrine-resistant setting. No 37 
naturally occurring ESR1 mutations have been reported in in-vitro models of BC 38 
either before or after the acquisition of endocrine resistance making functional 39 
consequences difficult to study. We report the first discovery of naturally occurring 40 
ESR1Y537C and ESR1Y537S mutations in MCF7 and SUM44 ESR1-positive cell-lines 41 
after acquisition of resistance to long-term-estrogen-deprivation (LTED) and 42 
subsequent resistance to fulvestrant (ICIR). Mutations were enriched with time, 43 
impacted on ESR1-binding to the genome and altered the ESR1-interactome. The 44 
results highlight the importance and functional consequence of these mutations and 45 
provide an important resource for studying endocrine resistance.  46 
 47 
 48 
  49 
 3
Introduction 50 
Over 70% of breast cancers (BC) are estrogen-receptor-α (ESR1) positive at 51 
diagnosis. Estrogen mediates its effects by binding to ESR1 leading to expression of 52 
genes controlling proliferation and cell survival. ESR1 has two distinct activation 53 
domains, AF-1 and AF-2. AF-1 is regulated by phosphorylation whilst AF-2 is 54 
integral to the ligand-binding domain (LBD) and associates with coactivators, 55 
controlling the ESR1 transcriptional complex (reviewed by 1). Classically, patients 56 
with ESR1-positive BC are treated with endocrine agents such as tamoxifen, 57 
aromatase inhibitors (AIs) or fulvestrant, which impede ESR1-signalling (reviewed 58 
by 2). Although over 50% of ESR1-positive patients show response to endocrine 59 
therapy and estrogen-deprivation therapy reduces BC mortality by 40% 3, a large 60 
proportion relapse with de novo or acquired resistant disease, making it one of the 61 
greatest challenges for BC research and treatment.  62 
 63 
Multiple mechanisms of resistance have been proposed, most of which have been 64 
identified using a limited number of ESR1-positive BC cell lines. These include 65 
aberrant cross-talk between ESR1 and growth factor signalling pathways or 66 
alterations in the balance of coactivators and corepressors (reviewed by 2, 4, 5).  67 
 68 
It has been known for many years that some mutations in ESR1 can lead to ligand-69 
independent activation, but until recently, such mutations appeared to have little 70 
clinical significance 6, as their presence in primary disease is rare. However, the 71 
prevalence of ESR1 mutations in metastatic tumours that have recurred or progressed 72 
after endocrine therapy is far higher 7, 8, 9. We have recently reported that the detection 73 
of these mutations in ctDNA of 39.1% of metastatic patients appears to correlate with 74 
clinical resistance to AIs 10. The majority of ESR1 mutations are located at two 75 
amino-acids in the LBD Y537N/C/S and D538G. Functional studies using ectopic 76 
expression of these mutations led to constitutive activity of ESR1 and conferred 77 
partial resistance to established clinical doses of tamoxifen and fulvestrant 11, 12. 78 
However, as these mutations were engineered, the role of cellular context during 79 
acquisition of resistance with time was not explored. 80 
 81 
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In this manuscript, we report for the first time, the identification of naturally occurring 82 
ESR1 mutations in BC cell models and their enrichment during acquisition of 83 
resistance to endocrine therapy. We show that the mutated ESR1 controls a cistrome 84 
similar to the ligand-dependent wild type (wt) ESR1 and associates with an altered 85 
protein-interactome enabling ligand-independent proliferation. Furthermore, these 86 
naturally occurring ESR1 mutants are sensitive to fulvestrant, suggesting that this and 87 
similar agents may have applicability in patients with tumours harbouring these 88 
mutations supporting our recent clinical data 13. 89 
 90 
Results 91 
Discovery of ESR1 mutations in models of endocrine resistance 92 
Previously, we reported the development of long-term-estrogen-deprived (LTED) 93 
derivatives from a number of ESR1-positive BC cell lines (including MCF7, 94 
HCC1428, T47D, ZR75.1 and SUM44) 14, 15. In general, estrogen deprivation leads to 95 
an initial quiescent population accompanied by cell death and after many weeks to 96 
outgrowth of a cell population that then proliferates independently of exogenous 97 
estrogen (Supplementary Figure 1a-d). The phenotype of the LTED cell lines varies 98 
leading to a context-specific sensitivity or resistance to additional agents 14.  99 
 100 
As ESR1 mutations have been associated with resistance to endocrine therapy, we 101 
explored whether these mutations or those of other genes were either enriched or 102 
acquired in the in vitro models described. Whole-exome sequencing from wt-MCF7 103 
and MCF7-LTED showed an ESR1Y537C mutation in the MCF7-LTED at an estimated 104 
variant allele frequency (VAF) of 30%, while it was undetectable in the wt-MCF7. 105 
The mutation was validated using digital droplet (dd) PCR (Fig. 1a, b).   106 
 107 
ESR1 mutations occur in LTED but not tamoxifen resistant cells 108 
As a result of this unexpected finding, we sequenced known hotspot regions for ESR1 109 
16 by Ion-Torrent in wt and LTED derivatives of MCF7, SUM44, HCC1428 and ZR-110 
75.1, together with tamoxifen-resistant (TAMR) derivatives of MCF7 and HCC1428 111 
and fulvestrant resistant (ICIR) derivatives of wt-MCF7, MCF7-LTED and ZR75.1-112 
LTED (Table 1 and Supplementary Figure 2). The ESR1Y537C mutant was detected in 113 
the MCF7-LTED-ICIR cells at a VAF of 48% that was confirmed by ddPCR (49.8%) 114 
(Supplementary Figure 3a) but was not detected in the wt-MCF7-ICIR cells. 115 
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Comparison of the two isogenic models showed that fulvestrant resistance 116 
(Supplementary Figure 3b) occurred irrespective of the mutation. Furthermore, both 117 
ICIR derivatives showed a marked reduction in ESR1 (Supplementary Figure 3c) and 118 
a concomitant drop in expression of estrogen-regulated genes (GREB1, PDZK1, PGR 119 
and TFF1) but equivalent expression of genes associated with proliferation when 120 
compared to their respective wild-type (Supplementary Figure 3d).  121 
 122 
Strikingly, analysis by Ion-torrent also revealed an ESR1Y537S heterozygous mutation 123 
in SUM44-LTED (VAF 47%). ESR1 mutations were confirmed by Sanger 124 
sequencing, RNA-sequencing, mass spectrometry and whole-exome sequencing 125 
(Supplementary Figure 4a-g). Exome sequencing did not reveal any additional 126 
mutated genes involved in AI resistance beyond the mutation in ESR1 nor did it 127 
reveal mutations in genes known to be drivers of BC 17 that might promote growth by 128 
other mechanisms (Supplementary Data 1). 129 
 130 
In order to determine if the ESR1Y537C VAF of 30% in the MCF7-LTED cells was 131 
indicative of a mixed population of cells harbouring either ESR1wt or ESR1Y537C, we 132 
assessed ESR1 copy number by fluorescent in-situ hybridisation (FISH) and exome 133 
sequencing. This revealed an allelic imbalance, which on average identified two or 134 
more wild-type copies of ESR1 and one mutant copy per cell in the MCF7-LTED, 135 
indicating 100% of the cell population harboured the mutation. In contrast, the 136 
MCF7-LTED-ICIR cells were enriched for two copies of ESR1 per cell similar to the 137 
SUM44-LTED, accounting for the VAF of 50% again indicating every cell in the 138 
given population contained a mutation (Supplementary Figure 5). 139 
 140 
Temporal enrichment of ESR1 mutations during estrogen deprivation 141 
Analysis by ddPCR over a time course showed that the ESR1Y537S mutation was 142 
detectable within 12 weeks following transfer of SUM44 cells to estrogen-free 143 
medium  (Fig. 1c). Thereafter, the VAF increased progressively up to 50%. In order 144 
to determine if the mutation was present in the parental population or was acquired as 145 
a result of the selective pressure of estrogen-withdrawal, we screened over 6x106 146 
matched parental SUM44 copies. Interestingly, the ESR1Y537S mutation was present in 147 
wt-SUM44 at an apparent frequency of approximately 1:1.000.000  (Fig. 1d), 148 
implying that the ESR1Y537S mutation pre-exists in a very small proportion of SUM44 149 
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cells. We further screened a second batch of SUM44-LTED and their corresponding 150 
parent cell line but no mutation was identified, suggesting this is not the only adaptive 151 
mechanism.  In order to control further the potential of contamination, we screened an 152 
equivalent number of ESR1-negative SKBR3 cells and no mutation was evident 153 
(Fig.1d). Finally, to address the possibility that the Y537C mutation was also resident 154 
at low frequency in MCF7 cells, we screened three independent batches, covering 155 
over 6 x106 copies, however we were unable to identify the Y537C mutation.  156 
 157 
ESR1Y537S drives ligand-independent transcription 158 
 To determine the function of ESR1Y537S, we performed ChIP-seq with antibodies for 159 
ESR1 in asynchronous wt-SUM44 in the presence of estrogen and SUM44-LTED in 160 
the absence of estrogen. Overlap of two replicate experiments called 28,647 and 161 
23,294 ESR1 binding events in wt-SUM44 and SUM44-LTED cells, respectively. 162 
The vast majority (80%) of the ESR1Y537S binding sites in SUM44-LTED cells were 163 
common to ESR1wt binding sites in estrogen-treated wt-SUM44 (Fig. 1e). Although 164 
4,702 differential binding sites were called in the SUM44-LTED cells, these were not 165 
unique, but represented enriched ESR1 binding i.e they also appeared in wt-SUM44 166 
and this was similarly the case for the 10,055 differential binding sites in wt-SUM44 167 
that occurred in the SUM44-LTED but were not enriched to the same level (Fig. 1f).  168 
 169 
Peak strength was evaluated at a number of target genes (Supplementary Figure 6a), 170 
where augmented ESR1Y537S binding was evident in SUM44-LTED compared to wt-171 
SUM44.  Furthermore, ChIP-qPCR validation assessing recruitment of ESR1Y537S 172 
together with FOXA1, a major pioneer factor for ESR1 18 and CBP required for an 173 
authentic ESR1 transcriptional complex 19, showed enhanced binding to the promoters 174 
of TFF1 and GREB1 in the SUM44-LTED compared to wt cell line (Supplementary 175 
Figure 6b).  176 
 177 
ESR1 binding sites in both cell lines showed a similar pattern of genomic distribution 178 
(Supplementary Figure 6c). Furthermore, the vast majority of binding motifs were 179 
similar for ESR1wt and ESR1Y537S however, significant enrichment for motifs 180 
representing the transcription factors ESR1, RARA, PAX2, ANDR and FOXA1 were 181 
evident in relation to the enriched ESR1 peaks found in SUM44-LTED, compared to 182 
wt-SUM44, which conversely showed increased GATA3 (Fig. 1g).   183 
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 184 
To identify the transcription targets of ESR1Y537S, we integrated ChIP-seq and RNA-185 
seq data from the respective cell lines. Gene set enrichment analysis (GSEA) showed 186 
that increased ESR1Y537S genomic binding correlated with increased transcription, 187 
whereas loss of binding correlated with down-regulation of genes in SUM44-LTED 188 
(Fig. 1h & Supplementary Figure 6d). We next used K-means clustering to compare 189 
the ESR1 binding patterns with expression of genes in wt-SUM44, wt-SUM44 after 190 
1-week of estrogen deprivation and the SUM44-LTED (20-weeks of estrogen-191 
deprivation). We identified four distinct gene sets 17 (Fig. 2a-c): GS1 consisted of 192 
classical estrogen-regulated genes such as TFF1, GREB1, PGR and CCND1 which 193 
decreased in expression after 1-week of deprivation but were elevated in the SUM44-194 
LTED. GS4 contained genes such as FOXA1 that were enriched after the first week of 195 
estrogen-deprivation and remained active in the LTED. GS2 and 3 included genes, 196 
such as MYC and JUN, which were down-regulated in the SUM44-LTED compared 197 
to wt-SUM44. Pathway analysis of the four clusters showed enrichment of ESR1-198 
signaling, epithelial-to-mesenchymal transition (EMT), mTORC1 complex activation 199 
and cholesterol homeostasis in the SUM44-LTED.  200 
 201 
To address this further, we assessed the metabolic capability of the wt-SUM44 and 202 
SUM44-LTED using Seahorse (Fig 2d). No significant change in glutamine 203 
dependency was evident between the two cell lines however, the SUM44-LTED 204 
showed a significantly higher glutamine capacity and fatty acid dependency compared 205 
to the wt-SUM44. The SUM44-LTED also showed a slight but significant decrease in 206 
glucose dependency.  207 
 208 
Lastly, we assessed the migratory ability of the cell lines (Fig. 2e). The SUM44-209 
LTED showed a 2-fold increase (p<0.001, Student’s t-test) in migration compared to 210 
wt-SUM44. 211 
 212 
Collectively, these findings suggest that ESR1Y537S mediates binding events that are 213 
functionally significant and lead to expression of genes controlling proliferation, 214 
survival and EMT, in a ligand-independent manner and whilst many ESR1 binding 215 
events are similar between the two lines, differences do exist and are probably the 216 
result of, or influenced by, the cellular context. 217 
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 218 
ESR1Y537S interacts with known ESR1-binding proteins 219 
In order to elucidate the impact of the Y537S mutation on the ESR1-interactome and 220 
proteome, we carried out comparative RIME (rapid immunoprecipitation with tandem 221 
mass spectrometry of endogenous proteins) and dimethyl-labelling 20 between wt-222 
SUM44 and SUM44-LTED (Fig. 3a & Supplementary Figure 7a,b). RIME 223 
demonstrated ESR1Y537S associated with a similar portfolio of proteins to those seen 224 
for ESR1wt including ESR1 itself, as well as, PGR, TLE3, HAT1 and FOXA1 21. 225 
However, increased association between ESR1Y537S GREB1 and FOXA1 was noted, 226 
which we confirmed by Co-IP (Supplementary Figure 7c). Quantitation of proteins by 227 
dimethyl-labelling showed increased abundance of TFF1 and a slight increase in 228 
ESR1 but not FOXA1 (Supplementary Figure 7d).  229 
 230 
Immunoblot analysis of wt-SUM44 and SUM44-LTED under basal growth conditions 231 
was assessed for changes in growth factor receptors and down stream pathways 232 
associated with endocrine resistance 2 as well as alterations in pESR1ser118, 233 
pESR1ser167 and PGR (Fig. 3b and Supplementary Figure 8). No significant changes in 234 
pEGFR or pERBB2 were apparent between the cell lines. A slight increase in 235 
pERK1/2 was seen in SUM44-LTED but no change in pAKTser473. The level of 236 
pESR1ser118 was greater in wt-SUM44 compared to the SUM44-LTED.  However, a 237 
slight increase in pESR1ser167 was noted in the LTED model (Fig. 3b). To address this 238 
further, both wt-SUM44 and SUM44-LTED were cultured in DCC medium in the 239 
absence or presence of estrogen. In this setting, ESR1 abundance and phosphorylation 240 
profiles were similar between the SUM44-LTED in the absence of estrogen and the 241 
wt-SUM44 in the presence of estrogen. Overall, these data showed the profile of the 242 
wt-SUM44 and SUM44-LTED was similar (Supplementary Figure 7e).  243 
 244 
As FOXA1 is an important pioneer factor regulating ESR1-driven transcription 22, 245 
and FOXA1 sites were enriched in our ChIP-seq analysis of SUM44-LTED cells, we 246 
hypothesised that it played a pivotal role in transcriptional regulation of ESR1Y537S. 247 
siRNA knockdown of FOXA1 significantly reduced proliferation of both wt-SUM44 248 
(42%, p<0.001, Student’s t-test) and SUM44-LTED cells although this was more 249 
pronounced in the latter (75%, p<0.001, Student’s t-test) (Fig. 3c). siFOXA1 also 250 
correlated with a significant reduction in expression of TFF1 and CCND1 (Fig. 3d), 251 
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suggesting FOXA1 plays a crucial role in the ligand-independent transcriptional 252 
activity of ESR1Y537S.  253 
 254 
CRISPR analysis shows ESR1Y537S controls ligand independence  255 
As kinase signalling has been strongly implicated in endocrine resistance resulting in 256 
ligand-independent activity of ESR1 2, we sought an approach that would reduce the 257 
effect of this confounding influence. In this setting, wt-MCF7, which harbour ESR1wt, 258 
were engineered to introduce the ESR1Y537S mutation using CRISPR-Cas9 genome 259 
editing. MCF7Y537S cells carry one endogenous ESR1 gene in which, ESR1wt has been 260 
mutated to code for the ESR1Y537S mutation, as well as ESR1wt. Detailed functional 261 
analyses of MCF7Y537S cells are described elsewhere 23. Proliferation assays in the 262 
absence of exogenous estrogen showed the MCF7Y537S was ligand-independent (Fig. 263 
4a). Furthermore, levels of ESR1 expression between the wt and the mutated cell line 264 
were similar (Fig. 4b and Supplementary Figure 8). Analysis of ESR1 ChIP-seq from 265 
wt-MCF7 and MCF7Y537S in the absence of exogenous estrogen showed 3602 266 
common peaks across the genome and 8094 unique binding events in MCF7Y537S 267 
(Fig. 4c, d). Furthermore, peak affinity was greater for ESR1Y537S across the genome 268 
whilst binding events were similarly distributed for both ESR1wt and ESR1Y537S (Fig. 269 
4e, f). Overlay of the binding events from ChIP-seq analysis with corresponding 270 
RNA-seq from MCF7Y537S showed increased expression of proliferation-associated 271 
genes and known estrogen-regulated genes, which was confirmed by protein 272 
expression (Fig. 4b, g and Supplementary Figure 8). This data suggests the mutation 273 
alone is sufficient to hold ESR1 in a conformation suitable for recruitment of 274 
coactivators together with the basal transcription machinery and that these mutations 275 
may not require altered kinase profiles to be active. Of note, treatment of both cell 276 
lines with estrogen revealed 74% concordance in ESR1 binding events suggesting 277 
ESR1Y537S remained responsive to ligand (Fig. 4h).  278 
 279 
Intersect of the ESR1 binding events in SUM44-LTEDY537S and MCF7Y537S (Fig. 4h) 280 
showed over 50% of the peaks called in MCF7Y537S were common to those in 281 
SUM44-LTEDY537S. Overlay of the common binding events with RNA-seq showed 282 
enrichment of genes associated with Hallmark pathways such as early (p-value= 10-72, 283 
hypergeometric test) and late (p-value= 10-43, hypergeometric test) estrogen 284 
responsiveness, EMT transition (p-value=10-18, hypergeometric test), mTORC1 285 
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signalling (p-value=10-12, hypergeometric test) and Fatty acid metabolism (p-value= 286 
10-9, hypergeometric test) (Supplementary Data 2). Nonetheless, differences between 287 
the cell lines highlight the influence of phenotypic nuances on the ESR1 function. 288 
 289 
ESR1wt and ESR1Y537C have altered genome-wide binding patterns  290 
Two MCF7-LTED derivatives were sequenced, of which one harboured an ESR1Y537C 291 
(MCF7-LTEDY537C) and the other ESR1wt (MCF7-LTEDwt) (as confirmed by ddPCR 292 
Supplementary Figure 9a), suggesting LTED itself may not always select for 293 
mutations.  Indeed, there are no previous reports of ESR1 mutations in LTED cells. 294 
Further interrogation of the whole exome sequencing data from both MCF7-LTED 295 
models, showed an increased mutational load in the MCF7-LTEDY537C compared to 296 
the MCF7-LTEDwt. However, no high impact mutations previously associated with 297 
AI-resistance 2 were evident in either cell line other than ESR1Y537C (Supplementary 298 
Data 1). Immunoblotting showed that while key signaling pathways appeared similar 299 
between the LTED derivatives, expression of PGR differed significantly 300 
(Supplementary Figure 9b). We therefore hypothesized that the mutant ESR1Y537C and 301 
ESR1wt controlled different ESR1-cistromes. To address this, genome-wide binding of 302 
ESR1 was assessed in both MCF7-LTED derivatives and the corresponding wt-303 
MCF7. Assessment of the distribution of ESR1 binding showed increased occupancy 304 
at the promoter (<1kb) in MCF7-LTEDwt (9.2%, p=10-94 Chi squared test) and MCF7-305 
LTEDY537C (28.4%, p=0 Chi squared test) compared to wt-MCF7 (3.3%). The 306 
converse was observed for the distal intergenic regions (Fig. 5a). To address this 307 
further, we used DiffBind and identified 4,744 differential binding events between the 308 
MCF7-LTEDwt and wt-MCF7, 13,824 between MCF7-LTEDY537C and wt-MCF7 and 309 
11,018 between MCF7-LTEDwt and MCF7-LTEDY537C (FDR<5%) (Supplementary 310 
Figure 9c,d). This suggested that the ESR1Y537C and ESR1wt in the MCF7-LTED cell 311 
lines control altered cistromes in comparison to wt-MCF7, but also differed between 312 
each other. Of interest, both LTED cell lines showed increased expression of GATA3, 313 
CDK1, RET and ESR1 compared to the parental cell line (Fig. 5b). However, MCF7-314 
LTEDY537C showed increased expression of estrogen-regulated genes such as PGR 315 
and TFF1 together with AREG, whilst MCF7-LTEDwt showed increased expression 316 
of BCL2 and XBP1 (Fig. 5b). K-means clustering of the ChIP-seq and RNA-seq data 317 
confirmed that the ESR1Y537C mutation appeared to function “classically” in the 318 
absence of ligand compared to MCF7-LTEDwt.  Noteworthy, both LTED derivatives 319 
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enriched for pathways associated with PI3K/AKT/mTORC compared to wt-MCF7 320 
but differed in the downstream impact of these pathways when comparing clusters 1 321 
and 3 (Fig. 5c-e).  322 
 323 
We next assessed the metabolic capability of the cell lines, which was similar for both 324 
capacity and dependency on glutamine, and glucose (Fig. 5f). However, the MCF7-325 
LTEDwt showed higher dependency on fatty acids (p<0.05, one-way ANOVA and 326 
Tukey’s test).  327 
 328 
Finally, and in keeping with the SUM44-LTED, both MCF7-LTED derivatives were 329 
highly migratory compared to wt-MCF7 (Fig. 5g).   330 
 331 
In order to further delineate the dependency of the MCF7-LTEDY537C on the mutant 332 
ESR1, we carried out a CRISPR-Cas9 reversion editing Y537C to Y537 (ESR1∆537C) 333 
(Supplementary Figure 10a,b). In keeping with our previous data, MCF7-LTEDY537C 334 
showed ligand-independent growth. Contrastingly, MCF7-LTED∆537C and wt-MCF7 335 
revealed limited proliferation in the absence of estrogen (Supplementary Figure 10c). 336 
Furthermore, MCF7-LTED∆537C switched to estrogen dependency and phenocopied 337 
the response of wt-MCF7 to fulvestrant (Supplementary Figure 10d,e). 338 
Immunoblotting and RT-qPCR showed that MCF7-LTED∆537C regain estrogen-339 
dependency for expression of target genes, PGR, TFF1, GREB1 and CTSD 340 
(Supplementary Figure 10f,g). Taken together, these data show that the ESR1Y537C 341 
mutation is paramount for the ligand-independent phenotype of MCF7-LTEDY537C 342 
cells.  343 
 344 
ESR1 mutations show altered responses to endocrine therapy  345 
One of the most clinically pressing questions relates to the sensitivity of ESR1 346 
mutations to endocrine therapy. Cell lines were treated with escalating concentrations 347 
of 4-hydroxy-tamoxifen (4-OHT) or fulvestrant in the presence or absence of estrogen 348 
(Fig. 6a-c and Supplementary Figure 8). In the absence of estrogen, both wt-MCF7 349 
and wt-SUM44 showed little sensitivity to fulvestrant, as expected. SUM44-LTED 350 
and both MCF7-LTED derivatives were sensitive to fulvestrant in the absence of 351 
estrogen confirming ESR1 ligand-independence, irrespective of mutation state. In the 352 
presence of estrogen, sensitivity to both 4-OHT and fulvestrant was reduced in the 353 
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low concentration range in SUM44-LTED compared to wt-SUM44. However, while 354 
ESR1Y537S was not inhibited by 4-OHT, it was by fulvestrant. Wt-MCF7, MCF7-355 
LTEDY537C and MCF7-LTEDwt all showed similar sensitivity to 4-OHT. However, 356 
MCF7-LTEDY537C in the presence or absence of estrogen, showed greater sensitivity 357 
to fulvestrant compared to MCF7-LTEDwt. The sensitivity of the MCF7-LTEDY537C 358 
model to the antiproliferative effect of fulvestrant was further supported in vivo (Fig 359 
6d). 360 
 361 
We subsequently assessed response to drugs inhibiting pathways associated with 362 
endocrine resistance such as mTORC (RAD001), ERK1/2 (U0126) and 363 
ERBB2/EGFR (lapatinib) 2. SUM44 derivatives were resistant to the antiproliferative 364 
effects of lapatinib and U0126 and showed similar sensitivity to RAD001. The MCF7 365 
derivatives revealed limited response to lapatinib. MCF7-LTEDY537C and wt-MCF7 366 
showed a similar response to RAD001 but not U0126, where MCF7-LTEDY537C 367 
showed marked sensitivity in keeping with the increased levels of pERK1/2 in this 368 
cell line. The MCF7-LTEDwt showed little anti-proliferative response to any of the 369 
agents tested suggesting this cell line has a high degree of kinase plasticity 370 
(Supplementary Figure 11a, b). 371 
 372 
 373 
 374 
Discussion  375 
Acquired resistance to endocrine therapy is a major clinical problem and the 376 
elucidations of pathways associated with relapse are of paramount clinical importance 377 
to facilitate improvement in treatment. While somatic mutations in ANDR have been 378 
strongly linked with lack of response to hormone therapy and/or agonist response to 379 
anti-androgens in prostate cancer, it is only recently that the importance of ESR1 380 
mutations in BC has been reported (reviewed by 7). In vitro studies using ectopic 381 
expression cassettes suggest that the most commonly found mutations Y537S and 382 
D538G, confer ligand-independence and exhibit reduced sensitivity to tamoxifen and 383 
fulvestrant 11, 12.  384 
 385 
We describe for the first time the identification of naturally occurring ESR1 mutations 386 
in ESR1 positive BC cell lines. Importantly, we show that estrogen-depletion selects 387 
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for cells harbouring ESR1 mutations, resulting in estrogen-independent growth and 388 
expression of the ESR1 transcriptome. We believe that normal culturing of BC cell 389 
lines in the presence of estrogen obviates the need for ESR1 mutations and that only 390 
with the strong selective pressure imparted by culturing in estrogen-depleted medium 391 
are alternative growth pathways, including ESR1 mutations enriched. Furthermore, 392 
estrogen-deprivation appears to be the primary point for enrichment, as ESR1 mutated 393 
cells did not appear to be augmented during acquisition of resistance to tamoxifen or 394 
fulvestrant in vitro. This observation is analogous to our recent clinical study in which 395 
ESR1 mutations in ctDNA of metastatic BC patients were found almost exclusively in 396 
patients that had become resistant to AI treatment 10, 13. Additionally, treatment with 397 
fulvestrant in vitro appeared to enrich for the pre-existing Y537C mutation (MCF7-398 
LTED-ICIR).  399 
 400 
ChIP-seq, analysis suggested that ESR1Y537S functions in a ligand-independent 401 
manner, largely recapitulating the estrogen-bound-ESR1wt cistrome, which was 402 
demonstrated by the fact that ER binding sites and their genomic distribution was 403 
overwhelmingly similar in wt-SUM44 and SUM44-LTED cells. The Y537S mutation 404 
lies near helix 12 (H12), which governs the ligand-regulated actions of ESR1 via AF-405 
2. Recent studies have suggested that Y537S enables H12 to undergo a 406 
conformational change exposing the AF2 cleft, facilitating recruitment of coregulators 407 
in the absence of hormone, leading to further stabilization of H12. In the same study, 408 
it was shown that Y537S also increased affinity for AIB1 24. Assessment of the 409 
ESR1Y537S interactome using RIME showed no increase in the association of the 410 
naturally occurring mutant ESR1 with AIB1 but did show increased association with 411 
FOXA1 and GREB1. One possible explanation for this difference is that the structural 412 
studies analysed only the ESR1 LBD and nuclear receptor interacting domain of 413 
AIB1 24 and thus cellular context was not explored.  414 
 415 
Despite this compelling data, indicating the mutant ESR1 is sufficient to drive 416 
adaptation to estrogen-deprivation, the cell lines, similar to clinical samples, are 417 
heterozygote for both wt and ESR1 mutant alleles. As such, we cannot conclusively 418 
differentiate between binding events due to wt and mutant ESR1, so it is possible that 419 
the wt allele predominates in LTED. However, there is no evidence in clinical 420 
samples that all ESR1 alleles are mutated in metastatic BC cases 11 12 25 26 27 28 . 421 
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Moreover, MCF7Y537S cells, generated by CRISPR-Cas9 mediated knockin 422 
mutagenesis, which are heterozygote for ESR1Y537S and express both wt and Y537S 423 
mutant ESR1, show estrogen-independent recruitment of ESR1 and coactivators to 424 
ESR1 binding regions 23. These cells demonstrate estrogen-independent expression of 425 
ESR1 target genes and grow in an estrogen-independent manner, validating the 426 
contribution of the Y537S mutation to estrogen independence when co-expressed 427 
with ESR1wt. 428 
A second caveat is the role of altered kinase signaling pathways that may arise from 429 
extended growth in estrogen-depleted culture conditions to generate LTED and post-430 
translational changes that may impact on the resistance phenotype. Our own studies 431 
and those of others have shown that altered kinase signaling can lead to ligand-432 
independent activation of ESR1 (reviewed by 2). Furthermore, ectopic expression of 433 
AKT has been shown to alter the genome-wide binding pattern of ESR1 29 and that 434 
EGF induces a transcriptional program distinct from estrogen 30. However, genomic 435 
profiling of SUM44-LTED cells harboring ESR1Y537S did not provide evidence for 436 
altered ESR1 binding patterns compared to wt-SUM44. Secondly, the CRISPR-Cas9 437 
derived MCF7Y537S cells showed estrogen-independence in the absence of prolonged 438 
culturing in estrogen-depleted conditions. Finally, CRISPR-Cas9 editing of the 439 
Y537C allele re-established estrogen-dependence in MCF7-LTED∆537C cells, 440 
demonstrating a requirement for the Y537C mutation for the estrogen-independence. 441 
Taken together, our results support the notion that activating mutations in the ESR1 442 
are sufficient for driving acquired resistance that does not necessitate changes in other 443 
signalling pathways.  444 
Moreover, our in vitro data indicate that ESR1Y537S/C mutations are responsive to 445 
fulvestrant, as ESR1 protein expression was downregulated (Fig. 6c), although 446 
suppression of growth was less pronounced at low concentrations of the drug, 447 
indicating partial resistance of ESR1Y537S but not ESR1Y537C. Nonetheless, at the 448 
predicted clinically achievable concentrations of fulvestrant31, 32, ESR1Y537S was as 449 
equally sensitive as the ESR1wt. This is in keeping with our previous clinical data, 450 
which suggests patients harbouring an ESR1 mutation show longer progression free 451 
survival when treated with fulvestrant versus exemestane 13. However, in contrast to 452 
Y537C, Y537S showed reduced sensitivity to 4-OHT. One explanation for these 453 
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observations is that, 4-OHT causes Y537S to stabilise H12 by the formation of a 454 
hydrogen-bond between 537S and E380, effectively reducing the potency of the drug. 455 
In contrast, binding of fulvestrant disorders H12. As such, some of the new 456 
SERM/SERD agents with enhanced pharmacokinetics capable of increasing the 457 
dynamics of H12 may show increased potency against this mutation 24.  458 
Interestingly, MCF7-LTEDwt show evidence of reduced ESR1 activity, with lower 459 
expression of estrogen-regulated genes such as PGR and increased expression of 460 
genes associated with anti-apoptotic activity 33. Unexpectedly, LTED cells expressing 461 
ESR1wt were also less sensitive to fulvestrant compared to ESR1Y537C. One 462 
explanation is that these cells already have elevated kinase activities and are thus less 463 
dependent on ESR1, highlighting once again the complexity of cellular context as 464 
well as mutation status on response to endocrine therapy.  465 
Recent genetic studies that have identified ESR1 mutations in metastatic, endocrine 466 
resistant BC indicate that these mutations result from the selective pressure imposed 467 
by inhibition of ESR1 activity by hormonal therapies. The results presented here 468 
provide support for this hypothesis. The independent BC cell line models identified 469 
here also provide an important resource for studying the relative contribution of ESR1 470 
mutations and alterations in other signalling pathways, that lead to endocrine 471 
resistance. Indeed, the genomic studies described herein provide support for the 472 
importance of kinase signalling cascades that have already been implicated in 473 
endocrine resistance by our studies, as well as those of other investigators. Our 474 
findings demonstrate that ESR1 mutations provide an important, albeit not the only 475 
driver of acquired endocrine resistance, concordant with the clinical observation that 476 
approximately 20% of metastatic tumours harbour mutant ESR1. Using resistance 477 
models featuring ESR1 mutations and those that do not involve ESR1 mutations 478 
should prove to be valuable in aiding patient management, and for assessing new 479 
treatment approaches for endocrine resistant BC. We and others will need to consider 480 
the presence and any phenotypic effects of these and possibly other acquired/selected 481 
mutations when using these derived cell lines for mechanistic or pharmacological 482 
studies and interpreting data from them.  483 
 484 
 485 
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Material and Methods 488 
Reagents 489 
Following antibodies were used for immunoblotting: pESR1ser167 (CST cat-5587, 490 
1:1000), pESR1ser118 (CST cat-2511, 1:1000), total-ESR1(Santa-Cruz sc8002, 1:800 491 
or Novacastra (NCL-ER-6F11), 1:1000), total-FOXA1 (Abcam Ab23738, 1:1000) 492 
total-PGR (Novocastra NCL-L-PGR, 1:500 or Santa Cruz sc-538, 1:200), pERBB2 493 
(CST-2243, 1:1000), total-ERBB2 (CST-4290, 1:1000), pEGFR (CST-3777, 1:1000), 494 
total-EGFR (CST-2232, 1:1000), pAKTser437 (CST-9271, 1:1000), total-AKT (CST-495 
9272, 1:1000), pERK1/2 (Sigma-Aldrich, 1:2000), total-ERK1/2 (CST-9102, 1:1000), 496 
TFF1 (Santa-Cruz sc28925, 1:200), RARA (Abcam Ab39971, 1:1000), cathepsin D 497 
(CTSD) (Abcam Ab6313, 1:2000), actin (Abcam Ab6276, 1:10000) and tubulin 498 
(Sigma T-9026, 1:2000). Secondary antibodies (horseradish peroxidase-linked, 499 
1:2000) were obtained from Dako. For ChIP, the following antibodies were used: 500 
ESR1 (Santa-Cruz sc543), CBP (Santa-Cruz sc369) and FOXA1 (Abcam Ab23738). 501 
17-β-estradiol (E) and 4-hydroxytamoxifen (4-OHT) were purchased from Sigma-502 
Aldrich and fulvestrant (ICI182780) from Tocris Bioscience. 503 
 504 
Cell culture  505 
Wt-MCF7, wt-HCC1428, wt-ZR75.1 and wt-SUM44 were purchased from the ATCC 506 
and Asterand. Cell lines were banked in multiple aliquots upon receipt to reduce risk 507 
of phenotypic drift and identity confirmed by short tandem repeats (STR) profiling. 508 
All cell lines were routinely screened for mycoplasma contamination. Wt cell lines 509 
were cultured in phenol red free RPMI supplemented with 10% foetal bovine serum 510 
(FBS) and exogenous estradiol (1nM). The respective LTED derivatives were 511 
cultured, as previously described 14, 15 in phenol red free RPMI supplemented with 512 
10% dextran charcoal stripped FBS (DCC medium). ICI-R and TAMR cell lines were 513 
cultured in their respective basal medium supplemented with 100nM fulvestrant 514 
(ICI182780) or 100nM 4-OHT. All experiments were performed under basal 515 
conditions unless otherwise stated. 516 
 517 
Proliferation assays 518 
Proliferation assays were performed as previously described for experiments 519 
involving drugs and siRNA studies 14, 15. In summary, cells were deprived of estrogen 520 
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for 48-72 hours prior to treatment with On-target plus® siRNA for human-siFOXA1  521 
or non-targeting pool (sicontrol) (Thermoscientific, Dharmacon). Knockdown 522 
efficacy was determined by qRT-PCR. For drug studies, cells were treated for 6 days 523 
with a medium change at day 3, as previously described 14. To analyse growth over 524 
time, cells were cultured as detailed above in DCC-medium with or without estradiol 525 
and data recorded using an IncuCyte ZOOM live cell analyser (Essen Biomedics). 526 
Three images per well were taken every 12 hours over a 6-day period.  527 
 528 
qRT-PCR  529 
RNA was extracted using the RNeasy kit (Qiagen), quantified and reverse-transcribed 530 
with SuperScriptIII First Strand Synthesis System (Invitrogen). Taqman gene 531 
expression assays (Applied Biosystems) were used to quantify TFF1 532 
(Hs00907239_m1 and Hs00170216_m1), PGR (Hs00172183_m1), GREB1 533 
(Hs00536409_m1), CTSD (Hs00157201_m1), ESR1 (Hs00174860_m1), CCND1 534 
(Hs00765553_m1) and the house-keeping genes FKBP15 (Hs00391480_m1) and 535 
GAPDH (Hs99999905_m1). The relative quantity was determined using ΔΔCt, 536 
according to the manufacturer's instructions (Applied Biosystems). 537 
 538 
Exome sequencing 539 
Exome libraries were generated with SureSelect Human All Exon V5 kit and 540 
sequenced (paired-end 100bp) on an Illumina HiSeq 2500. Reads were aligned to 541 
GRCh37-lite-build37 using BWA mem  (v0.7.12-r1039) 34, sorted with samtools 542 
(v1.2) 35 and further processed using picard tools (http://picard.sourceforge.net) 543 
(v1.128) with default parameters. SNVs were detected using VarScan v2.3.5 36 with 544 
default parameters (except --mpileup 1, --output-vcf) and wild-type cell samples as 545 
baseline. Multi-mapped reads were excluded and Base Alignment Quality (BAQ) was 546 
turned off for pileup with samtools. To get high confidence somatic mutations, SNVs 547 
were filtered by using: i) processSomatic of VarScan with empirically-derived 548 
criteria: minimum VAF in LTED cells: 0.10, maximum VAF in wild-type: 0.05, P-549 
value = 0.07; ii) fpfilter.pl from VarScan together with bam-readcount (--min-base-550 
quality 15, --min-mapping-quality 1) to reduce number of false positives. Variants 551 
were annotated using SnpEff v4.1 B 552 
(http://snpeff.sourceforge.net/SnpEff_manual.html). Mutations were annotated with 553 
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Tier levels 37 using BedTools v2.22.1 38. ascatNGS 554 
(https://github.com/cancerit/ascatNgs) was used to generate LogR and BAF values. 555 
Data has been deposited in the sequence read archive: BioProject ID PRJNA390496. 556 
 557 
Ion Torrent 558 
DNA was amplified using Ion AmpliSeq™ Library Kit 2.0 (Life Technologies), 559 
digested, Ion XpressTM Barcode adapters ligated and purified with Agencourt AMPure 560 
XP magnetic beads (Beckman Coulter). Libraries were quantified by qPCR using an 561 
Ion Library Quantification Kit (Life Technologies), templated on the Ion OneTouch2 562 
System (Life Technologies) and sequenced on the Ion PGM System (Life 563 
Technologies). Reads were aligned by the PGM server with standard settings to the 564 
reference genome hg19, samtools v1.2 was used to calculate the on-target coverage. 565 
IonReporterTM (v4.4) was used for mutation calling (parameters: Data Quality 566 
Stringency= 12, Downsample To Coverage= 4000, SNP/InDel/MNP Min Cov Each 567 
Strand= 50, SNP/InDel/MNP Min Variant Score= 15, SNP/InDel/MNP Min 568 
Coverage= 250, Hotspot Min Variant Score= 6, Hotspot Min Coverage= 150). All 569 
mutations called were manually reviewed in IGV and included in the analysis if they 570 
had a VAF ≥1%. 571 
 572 
ddPCR 573 
ddPCR assays for the ESR1 mutations Y537S and Y537C using Taqman probes was 574 
used as previously described 10. Very low frequency mutations were only considered 575 
to be present if two or more FAM-positive droplets were detected in the total of the 576 
wt sample.  577 
 578 
Cycle sequencing for validation 579 
ESR1 mutations were validated by cycle sequencing by eurofins genomics (Eurofins). 580 
DNA was amplified using forward primer 5’- AAGTGGCTGCAGGGAGAGT-3’ 581 
and reverse primer 5’- TGGTGCATGATGAGGGTAAA-3’. 582 
 583 
Fluorescence in situ hybridisation (FISH)  584 
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FISH probes hybridising at 6q25 (ESR1) and chromosome-6 (CEN6) were purchased 585 
from Empire Genomics. Cell pellets were fixed in 4% paraformaldehyde and paraffin-586 
embedded. Five-micron sections were subjected to the SwiftFISH rapid hybridization 587 
protocol (Empire Genomics), according to the manufacture’s instructions. Sections 588 
were mounted in DAPI-containing Vectashield (Vector). FISH probes signals were 589 
analysed using fluorescent microscope (Leica).  590 
 591 
RNA-seq 592 
Libraries were created after Ribo-zero rRNA removal kit (Illumina) using NEBNext 593 
Ultra Directional RNA (NEB) or Truseq Stranded Total RNA (Illumina) Library Prep 594 
Kit and sequenced using the HiSeq2500 (paired end 100bp v4 chemistry). Tophat 595 
(v2.1) and Cuffdiff (v2.2.1) 39 using default parameters (GSE100075). Kmeans 596 
clustering was performed using the kmeans function in the stats package in R.  The 597 
number of clusters used was determined by the number of clusters generated in 598 
unsupervised clustering using hclust (method = complete) function in R with of a 599 
matrix of correlation-based distances using the spearman method. 600 
 601 
ChIP-seq 602 
ChIP-qPCR and ChIP-seq were performed, as previously described 14, 40. Paired-end 603 
50 bp ChIP-seq data were generated by rapid-mode HiSeq. Reads were aligned to the 604 
Human Reference Genome (assembly hg19) using BWA 34 removing all reads with a 605 
quality score <15. Peaks were called using MACS2 (v2.1.0.20150420) 41 with default 606 
parameters. Only binding events that occurred in two biological replicates were 607 
considered differential binding sites using Diffbind v1.14.5 42 and R v3.2.1. Motif 608 
analysis was performed using centrimo (500bp centered on summit of peak) 609 
(http://meme-suite.org/) (GSE100074). Bar charts were generated with ChIPseeker 610 
package in R 43. 611 
 612 
GSEA 613 
Integration of RNA-seq and ChIP-seq diffBind data were carried out using GSEA, as 614 
previously described 44. In summary, all genes assessed using RNA-seq were ranked 615 
and weighted by their mean Log2 fold change. Lists of genes that overlapped with 616 
 21
regions showing significant differential binding were identified. These data were then 617 
analysed using the GSEA v2.0.13 GSEA Pre-ranked tool. The default setting was 618 
applied. Finally, additional analysis of gene sets (e.g. overlaps between significant 619 
binding events and closest genes that are significantly differentially expressed) were 620 
performed using the Molecular Signature Database 621 
(http://software.broadinstitute.org/gsea/msigdb/annotate.jsp) to compute overlaps with 622 
Hallmark gene sets that represent well-defined biological states or processes. 623 
Significance of overlap between gene sets was determined by hypergeometric test. 624 
 625 
RIME and dimethyl-labelling 626 
RIME 21 and stable isotope dimethyl-labelling 20 were performed, as previously 627 
described. The wt-SUM44 and SUM44-LTED were labelled with the medium and 628 
light isotope reagent, respectively. Labelled samples were pooled at an approximate 629 
1:1 ratio, dried down and fractionated using 12cm IPG strip pH 3-10, as previously 630 
described 45. RIME and dimethyl-label fractions were desalted (SUM SS18V, The 631 
Nest Group Inc) and run through LC-MS/MS using LTQ Velos Orbitrap MS. The 632 
data acquisition mode was set, as previously described 45. Raw data for RIME and 633 
dimethyl-labelling were analysed using MaxQuant 1.5.1.0 45, 46. Search parameters 634 
were as previously described 45. All proteomics data are deposited within the PRIDE 635 
database (PXD004807).  636 
 637 
Identification of Mutation at Protein Level using ddMS2/PRM 638 
ESR1-RIME samples were subjected to ddMS2-PRM analysis in order to verify the 639 
presence of wt and mutated serine or cysteine in the SUM44-LTED and MCF7-LTED 640 
samples, respectively (Supplementary Data 3). The analysis was performed using a Q-641 
Exactive HF mass spectrometer (Thermo Scientific, Hemel Hempstead, UK).  For 642 
each analysis, three biological replicates with two technical replicates were run. 643 
Heavy peptides were purchased from Thermo Fischer Scientific (PEPOTEC, grade 3). 644 
Reversed phase chromatography was performed on a Dionex UltiMate 3000 RSLC 645 
nano system (Thermo Fisher Scientific, Hemel Hempstead, UK) using an Acclaim 646 
PepMap100 C18 trap cartridge (0.5 mm i.d. x 5 mm, 5 µm bead size, 100 Å pore size; 647 
loaded in a bi-directional manner).  Peptides were resolved on a 75 µm I.D. 50 cm 648 
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C18 Easy-Spray packed emitter column (2 µm particle size; PepMap RSLC, Thermo 649 
Scientific, Hemel Hempstead, UK) over 90 min using a three-step gradient of 96:4 to 650 
50:50 buffer A:B (t = 0 min 4% B, 0.5 min 4% B, 12.0 min 10% B, 43.0 min 25% B, 651 
90.0 min 50% B) (buffer A: 2% acetonitrile/0.1% formic acid; buffer B: 80% 652 
acetonitrile/0.1% formic acid) at 250 nL per min. Peptides were ionised by 653 
electrospray ionisation using 1.8 kV applied using the Easy-Spray ion Source.  654 
Sample was infused into the mass spectrometer directly from the packed emitter (5 655 
µm exit bore).  The ion transfer tube was heated to 275°C and the S-lens set to 50%.  656 
MS/MS were acquired using parallel reaction monitoring (PRM) and data dependent 657 
(ddMS2) acquisitions based on a full FT-MS scan from 350 to 1850 m/z at 120,000 658 
resolution, with a target Automatic Gain Control (AGC) value of 3,000,000 and a 659 
maximum injection time of 50 ms. No internal lock mass calibrant was used.  8 PRM 660 
scans were triggered (FT-Orbitrap scans at 30,000 resolution, AGC target 2e5, 100 ms 661 
maximum injection time, normalised collision energy 35) if an ion from scheduled 662 
inclusion list was present.  Then, the top 5 most intense ions were fragmented by 663 
higher energy collision-induced dissociation (HCD) and dynamically excluded for 20 664 
s (FT-Orbitrap scans at 30,000 resolution, AGC target 1e5, activation time 10 ms, 50 665 
ms maximum injection time, normalised collision energy 28, selected first mass at 666 
140 m/z).  Precursor ions with unknown or single charge states were excluded from 667 
selection. Data analysis of raw MS/MS was carried out using Mascot V2.3 via 668 
Proteome Discoverer v1.4. Peak lists were searched against the human Uniprot 669 
FASTA database (20,305 sequences) containing the wild-type and mutant sequence. 670 
Spectra were searched for a match to fully-tryptic peptides with up to two missed 671 
cleavage sites. Search parameters were chosen as follows: Serine/threonine 672 
phosphorylation, Protein N-terminal acetylation, Peptide N-term glutamine to 673 
pyroGlu and oxidation of methionines were all considered as variable modifications, 674 
whereas Cysteine carbamidomethylation was selected as a fixed modification. 675 
Precursor ion mass tolerance was set to 15 ppm for the first search, fragment ion mass 676 
tolerance for ion analysed spectra was set to 0.02 Da. Resulting peptide and protein 677 
lists were grouped and validated using Scaffold v4 (Proteome Software Inc., Portland, 678 
OR). Protein identifications were automatically accepted if they contained at least two 679 
unique peptides assigned at 1% FDR.  The raw data has been deposited in Passel 680 
(PASS01062). 681 
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 682 
Immunoblotting 683 
Whole-cell extracts were generated from cells cultured under basal conditions or DCC 684 
medium with or without the addition of estrogen for comparative studies where noted. 685 
Equal amounts of protein resolved by SDS-PAGE and subjected to immunoblot 686 
analysis. Antigen-antibody interactions were detected with ECL-reagent (Amersham, 687 
UK) using the antibodies referred above.  688 
   689 
CRISPR-Cas9 mediated generation of the MCF7-LTED∆537C cells  690 
Gene knockins for a modified ESR1 exon 8, encoding a wild-type open reading frame 691 
with silent mutations to facilitate PCR analysis, were made using CRISPR-Cas9 692 
mediated homologous recombination in MCF7-LTEDY537C cells. ESR1 Gene 693 
targeting was carried out using CRISPR 4834093 (5’- 694 
GAGTGCTGAAATCCCTAGAA-3’) cloned into a guide-RNA expression plasmid (a 695 
gift from George Church; Addgene plasmid # 41824), as described previously 23.  The 696 
target sequence for this CRISPR is located in intron 7, on the antisense strand, 73nt 697 
from the start of ESR1 Exon 8.  For making the gene knockin, a previously described 698 
ESR1 exon 8 Y537S gene targeting donor construct 23 was modified by site-directed 699 
mutagenesis to change codon 537 from Serine (TCT) to Tyrosine (TAT), as found in 700 
the wild-type sequence. Additional mutations, to destroy the PAM for CRISPR 701 
4834093, were made by changing a run of four C nucleotides, located 77nt 5’ to the 702 
start of ESR1 Exon 8, to four G nucleotides.  Genome editing, detection of gene 703 
targeting events and sequence characterisation of gene targeted alleles were carried 704 
out as described previously 23, with the exception that following transfection, cells 705 
were recovered in full medium supplemented with 10% FCS, and Exon 8 knockin 706 
clones identified through stochastic cloning.  707 
 708 
Energy Phenotype and Mito Fuel Flex Analysis 709 
SUM44 and MCF7 cells were plated at a confluency of 1.0 x 104 per well in a 96-well 710 
Searhorse cell culture microplates and incubated in a 5% CO2 incubator at 37 °C 711 
overnight. The next morning, culture media was replaced with pH-adjusted (pH = 7.4 712 
± 0.1) bicarbonate-free DMEM with 10 mM glucose, 1 mM sodium pyruvate, and 2 713 
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mM L-Glutamine. The plate was then incubated at 37 °C for 1 hr in a non-CO2 714 
incubator. For the Mito Fuel Flex test, oxygen consumption rates were measure using 715 
the Searhorse XF Mito Fuel Flex Test Kit (Agilent, 103260-100) on an XFe96 716 
Analyzer. Cell numbers were normalized using CyQuant (ThermoFisher, C35012). 717 
 718 
Cell Migration Assay  719 
Cells growing in basal media were washed several times with phenol red free 720 
RPMI1640 containing 1% DCC-FBS. A total of 2.5 x 104 cells were seeded into the 721 
upper chambers of Corning FluoroBlok 96-multiwell insert system plates (Corning, 722 
UK). The lower chambers were filled with RPMI1640 containing 1% DCC-FBS plus 723 
100ng/ml human recombinant EGF, as chemo-attractant, and plates were incubated at 724 
37°C. After 16 hours, the medium was removed from the lower chambers and wells 725 
were washed with PBS. PBS containing 1μM calcein AM (Invitrogen) was added to 726 
the lower chambers and the plates were incubated at 37°C for 30 min. Fluorescence 727 
intensity was measured from the bottom of the plates using a 490nm excitation filter 728 
and a 520nm emission filter in a Victor X5 plate reader (PerkinElmer). Data is 729 
expressed as the mean of 8 replicates technical replicates. 730 
 731 
Human tumour xenografts modelling relapse on AI therapy  732 
In vivo studies were carried out in ovariectomized 8- to 12-week-old female BALB/c- 733 
nude mice in accordance with Home Office guidelines and approved by the Institute 734 
of Cancer Research Ethics Committee. Xenografts modelling patients resistant to AI 735 
were initiated by innoculating MCF7-LTEDY537C (107) cells in basement membrane 736 
matrix (Matrigel; BD Biosciences) into the right flank of each animal. Once tumours 737 
reached c. 7mm in size, they were size matched and mice treated with either 5mg per 738 
kg fulvestrant once per week or vehicle control. The study operator was blinded to 739 
treatment. Tumour growth was assessed twice weekly in both arms by caliper 740 
measurements of the two largest diameters. Volumes were then calculated according 741 
to the formula: a × b2 × π/6, where a and b are orthogonal tumour diameters. Tumour 742 
volumes were then expressed as median relative fold change in volume at the start of 743 
treatment. At the end of study, data was available for 7 animals in the control arm and 744 
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9 animals in the fulvestrant treatment arm. Overall statistical differences between the 745 
treatment and control arms were calculated using an unpaired t-test.  746 
 747 
Statistics analysis 748 
Statistical methodologies pertinent to each method is held within the sections above. 749 
 750 
Data Availability 751 
The data supporting the finding from this manuscript have been deposited as follows. 752 
Whole exome sequencing has been deposited in the sequence read archive BioProject 753 
ID PRJNA390496. RNAseq and ChIP-seq data have been deposited with the NCBI 754 
gene expression omnibus (GEO) (http://ncbi.nlm.nih.gov/geo/): ChIP-seq data for wt-755 
MCF7, MCF7-LTEDwt, MCF7-LTEDY537C wt-SUM44 and SUM44-LTED 756 
(GSE100074), RNA-seq (GSE100075) for wt-MCF7, MCF7-LTEDwt, MCF7-757 
LTEDY537C, wt-SUM44 and SUM44-LTED. CRISPR-cas9 MCF7Y537S ChIP-seq and 758 
RNA-seq data  (GSE78286) 23. All proteomics datasets are deposited within the 759 
PRIDE database (PXD004807) or Passel (PASS01062) for targeted sequencing. 760 
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Figure Legends 967 
 968 
Figure 1. Identification and characterisation of ESR1 mutations in models of 969 
endocrine resistance (a) Visualisation of ESR1Y537C identified during exome 970 
sequencing. (b) Digital droplet PCR (ddPCR) showing the presence of the ESR1Y537C 971 
mutation in MCF7-LTED. (c) ddPCR showing the presence of the ESR1Y537S mutation 972 
in SUM44-LTED. Temporal analysis showing enrichment of the mutation from wk12 973 
post estrogen-deprivation. (d) ddPCR showing the presence of ESR1Y537S at low 974 
variant allele frequency (VAF) in wt-SUM44 but not in SKBR3. (e) Overlap between 975 
wt-SUM44 and SUM44-LTED ESR1 binding sites and corresponding heatmap. The 976 
heatmap depicts binding peak intensities, which are common or different between the 977 
two cell lines. The window represents ± 5kb regions from the centre of the binding 978 
event. (f) Comparison of the average read count between wt-SUM44 and SUM44-979 
LTED showing peak affinity for the common and different binding events between 980 
the two cell lines. (g) Motif analysis of common and augmented ESR1 peaks from wt-981 
SUM44 versus SUM44-LTED. P-value of “common peaks” based on average of 3 982 
random selections of 2150 peaks to approximately match the number of peaks within 983 
the “augmented peak” comparisons. (h) GSEA was conducted comparing RNA-seq 984 
with ESR1 induced binding events in SUM44-LTED. ChIP-seq analysis was carried 985 
out using data from two biological replicates and RNA-seq from 3 biological 986 
replicates. 987 
 988 
Figure 2. ESR1Y537S controls proliferation, EMT and altered metabolism in 989 
SUM44-LTED (a) Heatmap depicting the changes in gene expression from four 990 
identified clusters of genes that were significantly differentially expressed and bound 991 
by ESR1wt (wt-SUM44) or ESR1Y537S (SUM44-LTED). (b) Average log2 differences 992 
in ESR1 binding for all genes within each cluster during the course of adaptation to 993 
LTED. (c) Pathway analysis of the four clusters, using GSEA. Sample labels 994 
represent: +E wk0= wt-SUM44, -E wk1= 1 wk E-deprived SUM44, -E wk 20= 995 
SUM44-LTED. (d) Metabolic dependency and capacity of wt-SUM44 and SUM44-996 
LTED on glutamine, fatty acid and glucose using a Seahorse XFe96 analyzer. (n=4 997 
technical replicates). (e) Comparison of the migratory ability of wt-SUM44 and 998 
SUM44-LTED (n=8 technical replicates). Error bars represent mean ± SEM. 999 
Significance was assessed by Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001.  1000 
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 1001 
Figure 3. Identification and functional analysis of the ESR1Y537S interactome (a) 1002 
MS-ARC depicting ESR1 RIME data conducted on SUM44-LTED (ESR1Y537S) 1003 
versus wt-SUM44 (ESR1wt) (n=3 biological replicates). The ranking is based on 1004 
SUM44-LTED/wt-SUM44 peptide (razor and unique) counts. The length of the line 1005 
represents the number of identified peptides. The longer the line, the greater the 1006 
interaction with ESR1Y537S compared to ESR1wt. The shorter cloud of lines shows the 1007 
high degree of commonality in ESR1 binding proteins between both cell lines. (b) 1008 
Immunoblotting showing alterations in expression of key protein markers previously 1009 
associated with endocrine resistant phenotypes. (c) Proliferation assays following 1010 
siFOXA1 in wt-SUM44 and SUM44-LTED relative to siControl in the presence and 1011 
absence of E (estradiol) (n=2 biological experiments with 8 technical replicates). (d) 1012 
Expression of estrogen-regulated genes, TFF1 and CCND1 following suppression of 1013 
FOXA1 (n=3 technical replicates). (Error bars represent mean ± SEM,  * p<0.05, ** 1014 
p<0.01, *** p<0.001, Significance was assessed by Student’s t-test). 1015 
 1016 
Figure 4. Characterisation of CRISPR-cas9 modified wt-MCF7 expressing 1017 
ESR1Y537S (a) Viability assay showing MCF7Y537S proliferate in the absence of 1018 
exogenous E compared to wt-MCF7  (n=6 technical replicates and 3 biolgical 1019 
replicates). Mean growth at day12 ± SEM relative to day 0. (b) Immunoblotting 1020 
showing alterations in the expression of ESR1, PGR, CTSD, TFF1 and RARA. (c) 1021 
Overlap between wt-MCF7 and MCF7Y537S ESR1 binding sites in the absence of E 1022 
and (d) corresponding heat map. The heatmap depicts binding peak intensities that are 1023 
common or different between the wt-MCF7 and MCF7Y537S. The window represents ± 1024 
5kb regions from the centre of the binding event. (e) Comparison of the average read 1025 
count between wt-MCF7 and MCF7Y537S in the absence of E showing peak affinity in 1026 
both cell lines (left) and those binding sites only significant in MCF7Y537S (right) (q-1027 
value <0.05). (f) Bar chart showing the genomic distribution of ESR1 binding sites 1028 
across the genome in both cell lines.  (g) Volcano plot showing changes in gene 1029 
expression by RNA-seq as a result of differential ESR1Y537S binding in MCF7Y537S 1030 
showing increased expression of estrogen-regulated and proliferation associated 1031 
genes. (h) Venn-diagrams showing intersect between wt-MCF7 and CRISPR 1032 
generated MCF7Y537S ChIP-seq peaks in response to ethanol (ETOH) or estradiol (E) 1033 
and intersect between SUM44-LTED and MCF7Y537S in the absence of E.  1034 
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 1035 
Figure 5. ESR1wt and ESR1Y537C regulate altered ESR1 cistrome (a) Bar chart 1036 
showing the genomic distribution of ESR1 binding sites across the genome in wt-1037 
MCF7, MCF7-LTEDwt and MCF7-LTEDY537C showing altered promoter (≤1kb) and 1038 
distal intergenic occupancy. (b) Volcano plots showing changes in gene expression by 1039 
RNA-seq in MCF7-LTEDY537C, MCF7-LTEDwt and wt-MCF7 (c) Heatmap depicting 1040 
the changes in gene expression of the four clusters comparing wt-MCF7 to MCF7-1041 
LTEDY537C, wt-MCF7 to MCF7-LTEDwt and MCF7-LTEDY537C to MCF7-LTEDwt. 1042 
(d) Average log2 differences for all genes within each set for wt-MCF7, MCF7-1043 
LTEDwt and MCF7-LTEDY537C. (e) Pathway analysis of the four clusters, using 1044 
GSEA. Data was derived from n=2 biological replicates for ChIP-seq and n=3 1045 
biological replicates for RNA-seq. (f) Metabolic dependency and capacity of wt-1046 
MCF7, MCF7-LTEDwt and MCF7-LTEDY537C on glutamine, fatty acid and glucose 1047 
using a Seahorse XFe96 analyzer (n=4 technical replicates). Significance was 1048 
assessed by one-way ANOVA and Tukey’s test. * p < 0.05, ** p < 0.01, *** p < 1049 
0.001 (g) Comparison of the migratory ability of wt-MCF7, MCF7-LTEDwt and 1050 
MCF7-LTEDY537C (n=8 technical replicates). Data shown is mean ± SEM. 1051 
Significance was assessed by Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001. 1052 
 1053 
Figure 6.  Anti-proliferative effect of endocrine therapy in ESR1 mutant and wt 1054 
cell lines (a) Proliferation assays assessing response of wt-SUM44 and SUM44-1055 
LTED and (b) wt-MCF7, MCF7-LTED wt and MCF7-LTEDY537C to escalating 1056 
concentration of fulvestrant ± E (estradiol) and 4-OHT plus E (estradiol). (c) 1057 
Treatment of wt-SUM44, SUM44-LTEDY537S, wt-MCF7, MCF7-LTEDY537C and 1058 
MCF7-LTEDwt with fulvestrant (10nM) results in loss of ESR1 expression 1059 
irrespective of mutation status (n=3 biological replicates consisting of n=8 technical 1060 
replicates). Data represents mean ± SEM (d) Xenograft models of MCF7-LTEDY537C 1061 
in response to vehicle or fulvestrant. Data represents median fold change in tumour 1062 
volume. Significance was assessed using an unpaired t-test. 1063 
 1064 
 1065 
 1066 
 1067 
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Table 1. Identification of naturally occurring ESR1 mutations in cell line models of 1069 
endocrine sensitive and resistant breast cancer.  1070 
 1071 
Cell Line No. Batches 
Screened 
No. Positive 
Batches 
Mutation VAF (%) 
wt-MCF7 4 0 - - 
MCF7-LTED 4 1 Y537C 30 
MCF7-TAMR 1 0 - - 
wt-MCF7-ICIR 1 0 - - 
MCF7-LTED-ICIR 1 1 Y537C 50 
wt-HCC1428 1 0 - - 
HCC1428-LTED 1 0 - - 
HCC1428-TAMR 1 0 - - 
wt-SUM44   2* 1 Y537S 0.0001 
SUM44-LTED   2* 1 Y537S 50 
wt-ZR75.1 1 0 - - 
ZR75.1-LTED 1 0 - - 
* Second batch originated from an independent laboratory  1072 
 1073 
 1074 
 1075 
 1076 
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